Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes

September 3, 2018 updated by: Novo Nordisk A/S

Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes

This trial is conducted in the United States of America (USA). This trial will compare the changes in HbA1c after 26 weeks of inhaled insulin and pioglitazone combination therapy versus pioglitazone treatment alone.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.

Study Type

Interventional

Enrollment (Actual)

196

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Alabama
      • Ozark, Alabama, United States, 36360
        • Novo Nordisk Investigational Site
      • Tuscaloosa, Alabama, United States, 35406
        • Novo Nordisk Investigational Site
      • Vestavia Hills, Alabama, United States, 35209
        • Novo Nordisk Investigational Site
    • Arizona
      • Tucson, Arizona, United States, 85741
        • Novo Nordisk Investigational Site
    • Arkansas
      • Little Rock, Arkansas, United States, 72204
        • Novo Nordisk Investigational Site
    • California
      • Bermuda Dunes, California, United States, 92203
        • Novo Nordisk Investigational Site
      • Escondido, California, United States, 92025
        • Novo Nordisk Investigational Site
      • Fresno, California, United States, 93720
        • Novo Nordisk Investigational Site
      • Huntington Beach, California, United States, 92646
        • Novo Nordisk Investigational Site
      • La Jolla, California, United States, 92037
        • Novo Nordisk Investigational Site
      • Northridge, California, United States, 91325
        • Novo Nordisk Investigational Site
      • Orange, California, United States, 92869
        • Novo Nordisk Investigational Site
      • Orange, California, United States, 92868
        • Novo Nordisk Investigational Site
      • Poway, California, United States, 92064
        • Novo Nordisk Investigational Site
      • Roseville, California, United States, 95661
        • Novo Nordisk Investigational Site
      • Sacramento, California, United States, 95821
        • Novo Nordisk Investigational Site
      • San Diego, California, United States, 92103-620
        • Novo Nordisk Investigational Site
      • Santa Barbara, California, United States, 93105
        • Novo Nordisk Investigational Site
      • Temecula, California, United States, 92591
        • Novo Nordisk Investigational Site
      • Tustin, California, United States, 92780
        • Novo Nordisk Investigational Site
      • Walnut Creek, California, United States, 94598
        • Novo Nordisk Investigational Site
    • Colorado
      • Arvada, Colorado, United States, 80005
        • Novo Nordisk Investigational Site
      • Colorado Springs, Colorado, United States, 80904
        • Novo Nordisk Investigational Site
    • Florida
      • Beverly Hills, Florida, United States, 34465
        • Novo Nordisk Investigational Site
      • Boca Raton, Florida, United States, 33433
        • Novo Nordisk Investigational Site
      • Clearwater, Florida, United States, 33759
        • Novo Nordisk Investigational Site
      • Hialeah, Florida, United States, 33010
        • Novo Nordisk Investigational Site
      • Hollywood, Florida, United States, 33021
        • Novo Nordisk Investigational Site
      • Lake Mary, Florida, United States, 32746
        • Novo Nordisk Investigational Site
      • Marianna, Florida, United States, 32446
        • Novo Nordisk Investigational Site
      • Melbourne, Florida, United States, 32901
        • Novo Nordisk Investigational Site
      • Miami, Florida, United States, 33136
        • Novo Nordisk Investigational Site
      • Niceville, Florida, United States, 32578
        • Novo Nordisk Investigational Site
      • Palm Harbor, Florida, United States, 34684
        • Novo Nordisk Investigational Site
      • Panama City, Florida, United States, 32401
        • Novo Nordisk Investigational Site
      • Pembroke Pines, Florida, United States, 33029
        • Novo Nordisk Investigational Site
      • Saint Petersburg, Florida, United States, 33709
        • Novo Nordisk Investigational Site
      • Tallahassee, Florida, United States, 32308
        • Novo Nordisk Investigational Site
      • Vero Beach, Florida, United States, 32960
        • Novo Nordisk Investigational Site
      • West Palm Beach, Florida, United States, 33401
        • Novo Nordisk Investigational Site
    • Georgia
      • Athens, Georgia, United States, 30606
        • Novo Nordisk Investigational Site
      • Atlanta, Georgia, United States, 30342
        • Novo Nordisk Investigational Site
      • Blue Ridge, Georgia, United States, 30513
        • Novo Nordisk Investigational Site
      • Dunwoody, Georgia, United States, 30338
        • Novo Nordisk Investigational Site
      • Powder Springs, Georgia, United States, 30127
        • Novo Nordisk Investigational Site
      • Roswell, Georgia, United States, 30076
        • Novo Nordisk Investigational Site
      • Sandy Springs, Georgia, United States, 30328
        • Novo Nordisk Investigational Site
      • Suwanee, Georgia, United States, 30024
        • Novo Nordisk Investigational Site
      • Tucker, Georgia, United States, 30084
        • Novo Nordisk Investigational Site
    • Hawaii
      • Honolulu, Hawaii, United States, 96814
        • Novo Nordisk Investigational Site
    • Idaho
      • Boise, Idaho, United States, 83702
        • Novo Nordisk Investigational Site
    • Illinois
      • Avon, Illinois, United States, 46123
        • Novo Nordisk Investigational Site
      • Chicago, Illinois, United States, 60607
        • Novo Nordisk Investigational Site
      • Chicago, Illinois, United States, 60611
        • Novo Nordisk Investigational Site
      • Chicago, Illinois, United States, 60612
        • Novo Nordisk Investigational Site
      • Peoria, Illinois, United States, 61615
        • Novo Nordisk Investigational Site
    • Indiana
      • Lafayette, Indiana, United States, 47904
        • Novo Nordisk Investigational Site
    • Iowa
      • Des Moines, Iowa, United States, 50314
        • Novo Nordisk Investigational Site
    • Kansas
      • Topeka, Kansas, United States, 66606
        • Novo Nordisk Investigational Site
      • Wichita, Kansas, United States, 67205
        • Novo Nordisk Investigational Site
    • Kentucky
      • Lexington, Kentucky, United States, 40503
        • Novo Nordisk Investigational Site
    • Maryland
      • Baltimore, Maryland, United States, 21201
        • Novo Nordisk Investigational Site
      • Prince Frederick, Maryland, United States, 20678
        • Novo Nordisk Investigational Site
    • Massachusetts
      • Marlborough, Massachusetts, United States, 01752
        • Novo Nordisk Investigational Site
      • Waltham, Massachusetts, United States, 02453
        • Novo Nordisk Investigational Site
    • Minnesota
      • Bloomington, Minnesota, United States, 55420
        • Novo Nordisk Investigational Site
    • Mississippi
      • Jackson, Mississippi, United States, 39216
        • Novo Nordisk Investigational Site
    • Missouri
      • Chesterfield, Missouri, United States, 63017
        • Novo Nordisk Investigational Site
      • Jefferson City, Missouri, United States, 65109
        • Novo Nordisk Investigational Site
      • Kansas City, Missouri, United States, 64111
        • Novo Nordisk Investigational Site
      • Saint Louis, Missouri, United States, 63141
        • Novo Nordisk Investigational Site
    • Montana
      • Billings, Montana, United States, 59102
        • Novo Nordisk Investigational Site
    • Nevada
      • Las Vegas, Nevada, United States, 89109
        • Novo Nordisk Investigational Site
      • Las Vegas, Nevada, United States, 89128
        • Novo Nordisk Investigational Site
    • New York
      • Syracuse, New York, United States, 13210
        • Novo Nordisk Investigational Site
    • North Carolina
      • Charlotte, North Carolina, United States, 28209
        • Novo Nordisk Investigational Site
      • High Point, North Carolina, United States, 27262
        • Novo Nordisk Investigational Site
      • Raleigh, North Carolina, United States, 27612
        • Novo Nordisk Investigational Site
      • Winston-Salem, North Carolina, United States, 27103
        • Novo Nordisk Investigational Site
    • North Dakota
      • Bismarck, North Dakota, United States, 58501
        • Novo Nordisk Investigational Site
    • Ohio
      • Canal Fulton, Ohio, United States, 44614
        • Novo Nordisk Investigational Site
      • Cincinnati, Ohio, United States, 45245
        • Novo Nordisk Investigational Site
      • Cincinnati, Ohio, United States, 45224
        • Novo Nordisk Investigational Site
      • Cleveland, Ohio, United States, 44122
        • Novo Nordisk Investigational Site
      • Cleveland, Ohio, United States, 44115
        • Novo Nordisk Investigational Site
      • Dayton, Ohio, United States, 45439
        • Novo Nordisk Investigational Site
    • Oklahoma
      • Clinton, Oklahoma, United States, 73601
        • Novo Nordisk Investigational Site
      • Oklahoma City, Oklahoma, United States, 73104-5020
        • Novo Nordisk Investigational Site
    • Oregon
      • Medford, Oregon, United States, 97504-8491
        • Novo Nordisk Investigational Site
    • Pennsylvania
      • Altoona, Pennsylvania, United States, 16602
        • Novo Nordisk Investigational Site
      • Beaver, Pennsylvania, United States, 15009
        • Novo Nordisk Investigational Site
      • Bensalem, Pennsylvania, United States, 19020
        • Novo Nordisk Investigational Site
      • Hershey, Pennsylvania, United States, 17033
        • Novo Nordisk Investigational Site
      • Norristown, Pennsylvania, United States, 19401
        • Novo Nordisk Investigational Site
    • South Carolina
      • Greer, South Carolina, United States, 29651
        • Novo Nordisk Investigational Site
    • Tennessee
      • Clarksville, Tennessee, United States, 37043
        • Novo Nordisk Investigational Site
      • Kingsport, Tennessee, United States, 37660
        • Novo Nordisk Investigational Site
    • Texas
      • Arlington, Texas, United States, 76014
        • Novo Nordisk Investigational Site
      • Dallas, Texas, United States, 75251
        • Novo Nordisk Investigational Site
      • Houston, Texas, United States, 77024
        • Novo Nordisk Investigational Site
      • Houston, Texas, United States, 77030
        • Novo Nordisk Investigational Site
      • Lewisville, Texas, United States, 75067
        • Novo Nordisk Investigational Site
      • Plano, Texas, United States, 75093
        • Novo Nordisk Investigational Site
      • San Antonio, Texas, United States, 78229
        • Novo Nordisk Investigational Site
    • Utah
      • Saint George, Utah, United States, 84790
        • Novo Nordisk Investigational Site
    • Virginia
      • Arlington, Virginia, United States, 22204
        • Novo Nordisk Investigational Site
      • Norfolk, Virginia, United States, 23502
        • Novo Nordisk Investigational Site
      • Richmond, Virginia, United States, 23249
        • Novo Nordisk Investigational Site
      • Warrenton, Virginia, United States, 20186
        • Novo Nordisk Investigational Site
    • Washington
      • Tacoma, Washington, United States, 98405
        • Novo Nordisk Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Type 2 diabetes
  • Current treatment with oral antidiabetes drugs (OADs) for at least 2 months
  • HbA1c between 7.0-11.0% if on OAD monotherapy
  • HbA1c between 7.0-10.0% if on OAD combination therapy
  • BMI less than or equal to 40 kg/m2

Exclusion Criteria:

  • Current regular smoking or regular smoking within the last 6 months
  • Current acute or chronic pulmonary disease (except for asthma)
  • Proliferative retinopathy requiring treatment
  • Clinically significant disease history including kidney or liver disease, or heart disease which limits physical activity or results in discomfort with physical activity
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: B
Drug: pioglitazone
Tablets, 45 mg/day.
Experimental: A
Drug: inhaled human insulin
Treat-to-target dose titration scheme, inhalation.
Other Names:
  • NN1998
Drug: pioglitazone
Tablets, 45 mg/day.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
HbA1c change from baseline
Time Frame: After 26 weeks of treatment
After 26 weeks of treatment

Secondary Outcome Measures

Outcome Measure
Time Frame
Fasting plasma glucose
Time Frame: after 26 weeks of treatment
after 26 weeks of treatment
Lipid profiles
Time Frame: after 26 weeks of treatment
after 26 weeks of treatment
Frequency of hypoglycaemic episodes
Time Frame: after 26 weeks of treatment
after 26 weeks of treatment
Glucose profiles
Time Frame: at pre- and post meals, bedtime and 3:00 am
at pre- and post meals, bedtime and 3:00 am
Change in body weight
Time Frame: after 26 weeks of treatment
after 26 weeks of treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Novo Nordisk A/S

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 29, 2006

Primary Completion (Actual)

March 18, 2008

Study Completion (Actual)

March 18, 2008

Study Registration Dates

First Submitted

December 14, 2006

First Submitted That Met QC Criteria

December 14, 2006

First Posted (Estimate)

December 15, 2006

Study Record Updates

Last Update Posted (Actual)

September 5, 2018

Last Update Submitted That Met QC Criteria

September 3, 2018

Last Verified

September 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NN1998-1683

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus, Type 2

Clinical Trials on inhaled human insulin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe